Survodutide (BI 456906): Glucagon/GLP-1 Dual Agonist

Survodutide (Boehringer Ingelheim/Zealand code BI 456906) is a once-weekly dual agonist of the glucagon and GLP-1 receptors. The GLP-1 side does the familiar incretin work; the glucagon side is the differentiator, adding an energy-expenditure and liver-fat angle that has made survodutide especially interesting for liver disease, not just weight.

Research Background

Survodutide was discovered by Boehringer Ingelheim and is co-developed with Zealand Pharma. It's a glucagon-based analog with a fatty-acid chain that supports weekly dosing, and its glucagon-to-GLP-1 activity ratio was tuned to capture the hepatic and energy-expenditure benefits of glucagon without pushing blood sugar up. After positive phase 2 results in both obesity and MASH in 2024, it moved into a phase 3 program (SYNCHRONIZE), including a dedicated cardiovascular outcomes trial.

How It Works

The GLP-1 receptor arm suppresses appetite through hypothalamic satiety pathways, slows gastric emptying, and supports glucose-dependent insulin secretion. The glucagon receptor arm adds two things GLP-1 alone doesn't: increased energy expenditure (thermogenesis) and a direct action on the liver that promotes fat oxidation and lipolysis. That hepatic effect is why survodutide has drawn attention for metabolic dysfunction-associated steatohepatitis (MASH), where reducing liver fat and fibrosis is the goal.

What the Research Shows

• Obesity, phase 2 (le Roux et al., *The Lancet Diabetes & Endocrinology*, 2024): across a dose range over 46 weeks, survodutide produced dose-dependent, statistically significant weight loss, with a tolerability profile in line with the GLP-1 class.
• MASH, phase 2 (Sanyal et al., *NEJM*, 2024): MASH improvement without worsening of fibrosis occurred in roughly 47–62% of survodutide participants (dose-dependent) versus about 14% on placebo — the primary endpoint. Fibrosis improved by at least one stage in about a third of treated participants, and a majority saw liver-fat reductions of 30% or more.
• Preclinical basis (Zimmermann et al., *Molecular Metabolism*, 2022): in animal models, the anti-obesity effect came from both increased energy expenditure (the glucagon arm) and reduced food intake (the GLP-1 arm), confirming the dual-mechanism rationale.

As with other incretin-based agents, gastrointestinal effects were the most common adverse events. Full citations are in the References section below.

Storage & Handling

Survodutide is supplied in lyophilized (freeze-dried) form. Store it at -20°C or below, protected from light and moisture. Reconstitute immediately before use with a sterile solvent, and avoid repeated freeze-thaw cycles.

Frequently Asked Questions

How is survodutide different from tirzepatide? Both are dual agonists, but they target different second receptors. Tirzepatide pairs GLP-1 with GIP; survodutide pairs GLP-1 with glucagon, which adds energy expenditure and a direct liver-fat effect.

Why is survodutide studied for liver disease? The glucagon-receptor arm acts on the liver to drive fat oxidation, so it's a natural candidate for MASH — and its phase 2 liver data (Sanyal 2024) were strong enough to earn regulatory Breakthrough Therapy attention.

What purity does Dynamite Research Peptides provide? Our survodutide is 99%+ purity with a Certificate of Analysis for every batch.

All products are for research use only — not for human or animal consumption.